Journal:Point-of-care RNA-based diagnostic device for COVID-19
| Full article title | Point-of-care RNA-based diagnostic device for COVID-19 |
|---|---|
| Journal | Diagnostics |
| Author(s) | Yang, Ting; Wang, Yung-Chih; Shen, Ching-Fen; Cheng, Chao-Min |
| Author affiliation(s) | National Tsing Hua University, National Defense Medical Center, National Cheng Kung University |
| Primary contact | Email: chaomin at mx dot nthu dot edu dot tw |
| Year published | 2020 |
| Volume and issue | 10(3) |
| Article # | 165 |
| DOI | 10.3390/diagnostics10030165 |
| ISSN | 2075-4418 |
| Distribution license | Creative Commons Attribution 4.0 International |
| Website | https://www.mdpi.com/2075-4418/10/3/165/htm |
| Download | https://www.mdpi.com/2075-4418/10/3/165/pdf (PDF) |
 |
This article should be considered a work in progress and incomplete. Consider this article incomplete until this notice is removed. |
Point-of-care RNA-based diagnostic device for COVID-19
At the end of 2019, the novel coronavirus disease 2019 (COVID-19), a fast-spreading respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was reported in Wuhan, China and has now affected over 123 countries globally. As of March 14, 2020, the death toll has exceeded 5,400, and there have been 145,000 confirmed cases, causing not only a huge medical health burden but also tremendous economic losses worldwide.[1] Unlike previous coronaviruses that caused large-scale epidemics, such as the Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS), the transmission rate for COVID-19 is much higher, with an average of two to three people becoming infected for every already infected person.[2] Currently, there are two primary methods for diagnosing COVID-19: (1) a lateral flow immunoassay, which is a common point-of-care (POC) diagnostic approach that detects antibodies against specific viruses (e.g., SARS-CoV-2) in patient samples; and (2) a molecular-based assay. The current standard approach for screening COVID-19 requires a reverse real-time polymerase chain reaction (rRT-PCR) assay, which can be carried out using a variety of clinical specimens, including bronchoalveolar lavage fluid, fibrobronchoscope brush biopsies, sputum, nasal swabs, nasopharyngeal swabs, feces, or blood.[3] This approach relies on expensive facilities, well-trained staff, and is often time-consuming, leaving a rapidly rising number of potential cases untested and opening a gaping hole in disease prevention efforts. Moreover, traveling to a clinical setting for testing increases the risk of spreading the disease and adds strain to a resource-limited healthcare system. For these reasons, an alternative, rapid, inexpensive, easy-to-use, and sensitive COVID-19 diagnostic tool must be developed for use by nonclinical individuals in their homes.
References
- ↑ "Coronavirus COVID-19 outbreak: Latest news, information and updates". Pharmaceutical Technology. Verdict Media Limited. March 2020. https://www.pharmaceutical-technology.com/special-focus/covid-19/coronavirus-covid-19-outbreak-latest-information-news-and-updates/. Retrieved 14 March 2020.
- ↑ Gates, B. (2020). "Responding to Covid-19 - A Once-in-a-Century Pandemic?". New England Journal of Medicine. doi:10.1056/NEJMp2003762. PMID 32109012.
- ↑ Wang, W.; Xu, Y.; Gao, R. et al. (2020). "Detection of SARS-CoV-2 in Different Types of Clinical Specimens". JAMA. doi:10.1001/jama.2020.3786. PMC PMC7066521. PMID 32159775. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066521.
Notes
This presentation is faithful to the original, with only a few minor changes to presentation. In some cases important information was missing from the references, and that information was added.
